Amgen (0R0T) Share Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R0T Analyst Ratings

Moderate Buy

10 Buy

11 Hold

2 Sell

Based on 23 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R0T Stock 12 Month Forecast

Average Price Target

$397.95

▼(-7.81% Downside)

Based on 23 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $397.95 with a high forecast of $460.00 and a low forecast of $230.00. The average price target represents a -7.81% change from the last price of $431.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"229":"$229","287":"$287","345":"$345","403":"$403","461":"$461"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":460,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$460.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":397.95238095238096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$397.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[229,287,345,403,461],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.25,439,440.75,442.5,444.25,446,447.75,449.5,451.25,453,454.75,456.5,458.25,{"y":460,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.25,434.2271062271062,431.20421245421244,428.18131868131866,425.15842490842493,422.13553113553115,419.1126373626374,416.0897435897436,413.0668498168498,410.04395604395603,407.0210622710623,403.9981684981685,400.97527472527474,{"y":397.95238095238096,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.25,421.3076923076923,405.36538461538464,389.4230769230769,373.4807692307692,357.53846153846155,341.59615384615387,325.6538461538462,309.71153846153845,293.7692307692308,277.8269230769231,261.88461538461536,245.9423076923077,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":278.647,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.886,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.582,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.863,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.308,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":336.302,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":379.645,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":348.472,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.834,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.816,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":357.118,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.411,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.25,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$460.00

Average Price Target$397.95

Lowest Price Target$230.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mohit Bansal

Wells Fargo

$435

Hold

0.78%

Upside

Assigned

09/04/26

Wells Fargo Reaffirms Their Hold Rating on Amgen (AMGN)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

08/28/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Amgen (NASDAQ: AMGN)

Louise Chen

Scotiabank

$450

Buy

4.25%

Upside

Reiterated

08/28/26

Amgen (AMGN) Gets a Buy from Scotiabank

Yaron Werber

TD Cowen

$452

Buy

4.71%

Upside

Reiterated

08/27/26

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Amsellem

Piper Sandler

$427→$457

Buy

5.87%

Upside

Reiterated

08/20/26

Amgen price target raised to $457 from $427 at Piper SandlerAmgen price target raised to $457 from $427 at Piper Sandler

Terence Flynn

Morgan Stanley

$351→$362

Hold

-16.14%

Downside

Reiterated

08/19/26

Amgen price target raised to $362 from $351 at Morgan StanleyAmgen price target raised to $362 from $351 at Morgan Stanley

Jasper Hellweg

Argus Research

$460

Buy

6.57%

Upside

Assigned

08/18/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)

Evan Seigerman

BMO Capital

$450

Buy

4.25%

Upside

Reiterated

08/17/26

Amgen (AMGN) Receives a Buy from BMO Capital

Carter Gould

Cantor Fitzgerald

$350→$400

Hold

-7.33%

Downside

Reiterated

08/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)

Salim Syed

Mizuho Securities

$303→$352

Hold

-18.45%

Downside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)

Emily Field

Barclays

$360→$380

Hold

-11.97%

Downside

Reiterated

08/13/26

Barclays Reaffirms Their Hold Rating on Amgen (AMGN)

Geoff Meacham

Citi

$345→$405

Hold

-6.17%

Downside

Reiterated

08/10/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

$343→$388

Hold

-10.11%

Downside

Reiterated

08/07/26

Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim

Chris Schott

J.P. Morgan

$350

Hold

-18.92%

Downside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mohit Bansal

Wells Fargo

$435

Hold

0.78%

Upside

Assigned

09/04/26

Wells Fargo Reaffirms Their Hold Rating on Amgen (AMGN)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

08/28/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Amgen (NASDAQ: AMGN)

Louise Chen

Scotiabank

$450

Buy

4.25%

Upside

Reiterated

08/28/26

Amgen (AMGN) Gets a Buy from Scotiabank

Yaron Werber

TD Cowen

$452

Buy

4.71%

Upside

Reiterated

08/27/26

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Amsellem

Piper Sandler

$427→$457

Buy

5.87%

Upside

Reiterated

08/20/26

Amgen price target raised to $457 from $427 at Piper SandlerAmgen price target raised to $457 from $427 at Piper Sandler

Terence Flynn

Morgan Stanley

$351→$362

Hold

-16.14%

Downside

Reiterated

08/19/26

Amgen price target raised to $362 from $351 at Morgan StanleyAmgen price target raised to $362 from $351 at Morgan Stanley

Jasper Hellweg

Argus Research

$460

Buy

6.57%

Upside

Assigned

08/18/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and CVS Health (NYSE: CVS)

Evan Seigerman

BMO Capital

$450

Buy

4.25%

Upside

Reiterated

08/17/26

Amgen (AMGN) Receives a Buy from BMO Capital

Carter Gould

Cantor Fitzgerald

$350→$400

Hold

-7.33%

Downside

Reiterated

08/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Quince Therapeutics (NASDAQ: QNCX) and Ocular Therapeutix (NASDAQ: OCUL)

Salim Syed

Mizuho Securities

$303→$352

Hold

-18.45%

Downside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Amgen (NASDAQ: AMGN)

Emily Field

Barclays

$360→$380

Hold

-11.97%

Downside

Reiterated

08/13/26

Barclays Reaffirms Their Hold Rating on Amgen (AMGN)

Geoff Meacham

Citi

$345→$405

Hold

-6.17%

Downside

Reiterated

08/10/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

$343→$388

Hold

-10.11%

Downside

Reiterated

08/07/26

Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim

Chris Schott

J.P. Morgan

$350

Hold

-18.92%

Downside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

AXGNAxoGen

ATECAlphatec Holdings

CABACabaletta Bio

ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

David AmsellemPiper Sandler

Success Rate

14/19 ratings generated profit

Average Return

+6.94%

Copying David Amsellem's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +6.94% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

19/19 ratings generated profit

Average Return

+30.33%

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.33% per trade.

2 Years

David AmsellemPiper Sandler

Success Rate

19/19 ratings generated profit

Average Return

+43.11%

Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R0T Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R0T has received 19 Buy Ratings, 22 Hold Ratings, and 3 Sell Ratings. 0R0T average Analyst price target in the past 3 months is 397.95.

Each month's total comprises the sum of three months' worth of ratings.

0R0T Financial Forecast

0R0T Earnings Forecast

Next quarter’s earnings estimate for 0R0T is $5.79 with a range of $5.48 to $6.16. The previous quarter’s EPS was $6.29. 0R0T beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0R0T has Performed in-line its overall industry.

0R0T Sales Forecast

Next quarter’s sales forecast for 0R0T is $10.05B with a range of $9.85B to $10.27B. The previous quarter’s sales results were $10.07B. 0R0T beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0R0T has Performed in-line its overall industry.

0R0T Stock Forecast FAQ

What is GB:0R0T’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 397.95.

What is GB:0R0T’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0R0T, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 11 hold ratings and 2 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 397.95. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $460.00 ,and the lowest forecast is $230.00. The average share price target represents -7.81% Decrease from the current price of $431.65.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of GB:0R0T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (0R0T) Share Forecast & Price Target

0R0T Analyst Ratings

0R0T Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

0R0T Analyst Recommendation Trends

0R0T Financial Forecast

0R0T Earnings Forecast

0R0T Sales Forecast

0R0T Stock Forecast FAQ

Detailed List of Analyst Forecasts